Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND
November 26 2019 - 4:00PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five
poster presentations at the 30th International Symposium on ALS/MND
in Perth, Australia. The posters will be presented on Thursday,
December 5, 2019 and Friday, December 6, 2019.
Thursday, December 5, 2019 (All times listed below are
local time in Perth)
Poster Session ATheme: Clinical Trials
and Trial Design
Title: Responder and Subgroup Analyses for
FORTITUDE-ALS, a Phase 2 Trial Study of Reldesemtiv in Patients
with ALSPresentation Time: 10:30 – 11:30 AMPoster Number:
CLT-21Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead
Investigator of FORTITUDE-ALS, Professor and Chair of Neurology at
Barrow Neurological Institute, and Professor and Executive Chair of
Neurology at the University of Arizona, Phoenix
Title: Quality of Life and Depression Measurements in
FORTITUDE-ALSPresentation Time: 10:30 – 11:30 AMPoster
Number: CLT-22Poster Presenter: Stacy Rudnicki, M.D., Senior
Medical Director, Clinical Research, Neurology, Cytokinetics
Title: Impact of ALSFRS-R progression rates on outcome
measures in FORTITUDE-ALS Presentation Time: 10:30 – 11:30
AMPoster Number: CLT-23Poster Presenter: Stacy Rudnicki, M.D.,
Senior Medical Director, Clinical Research, Neurology,
Cytokinetics
Title: Utilization of Durable Medical Equipment in
FORTITUDE-ALSPresentation Time: 10:30 – 11:30 AMPoster
Number: CLT-20Poster Presenter: Stacy Rudnicki, M.D., Senior
Medical Director, Clinical Research, Neurology, Cytokinetics
Friday, December 6, 2019
Poster Session BTheme: Biomedical and
Clinical Work in Progress
Title: People Living with ALS and Their Caregivers’
Input into Drug Development in EuropePresentation Time:
6:00 – 7:00 PMPoster Number: WP-14Poster Presenter: Miriam Galvin,
Ph.D., Academic Unit of Neurology, Trinity Biomedical Sciences
Institute, Trinity College Dublin
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators and best-in-class
muscle inhibitors as potential treatments for debilitating diseases
in which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating
with Amgen Inc. (Amgen) to develop omecamtiv mecarbil, a
novel cardiac muscle activator. Omecamtiv mecarbil is the subject
of an international clinical trials program in patients with heart
failure including GALACTIC-HF and
METEORIC-HF. Amgen holds an exclusive worldwide license
to develop and commercialize omecamtiv mecarbil with a sublicense
held by Servier for commercialization in Europe and
certain other countries. Cytokinetics is collaborating
with Astellas Pharma Inc. (Astellas) to develop
reldesemtiv, a fast skeletal muscle troponin activator (FSTA).
Astellas holds an exclusive worldwide license to develop and
commercialize reldesemtiv. Licenses held by Amgen and
Astellas are subject to specified co-development and
co-commercialization rights
of Cytokinetics. Cytokinetics is also developing
CK-274, a novel cardiac myosin inhibitor that company scientists
discovered independent of its collaborations, for the potential
treatment of hypertrophic
cardiomyopathies. Cytokinetics continues its over 20-year
history of pioneering innovation in muscle biology and related
pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
For additional information
about Cytokinetics, visit www.cytokinetics.com and follow
us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics’ and its partners’
research and development activities; the Phase 2 clinical study of
reldesemtiv in patients with ALS, including that such results may
support progression of reldesemtiv into a potentially pivotal Phase
3 clinical trial; the potentially beneficial effects of
reldesemtiv; and the properties and potential benefits of
Cytokinetics’ other drug candidates. Such statements are based on
management's current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the
development, testing, regulatory approvals for trial commencement,
progression or product sale or manufacturing, or production of
Cytokinetics’ drug candidates that could slow or prevent clinical
development or product approval; Astellas’ decisions with respect
to the design, initiation, conduct, timing and continuation of
development activities for reldesemtiv; Cytokinetics may incur
unanticipated research and development and other costs or be unable
to obtain additional financing necessary to conduct development of
its products; standards of care may change, rendering Cytokinetics’
drug candidates obsolete; competitive products or alternative
therapies may be developed by others for the treatment of
indications Cytokinetics’ drug candidates and potential drug
candidates may target; and risks and uncertainties relating to the
timing and receipt of payments from its partners, including
milestones and royalties on future potential product sales under
Cytokinetics’ collaboration agreements with such partners. For
further information regarding these and other risks related to
Cytokinetics’ business, investors should consult Cytokinetics’
filings with the Securities and Exchange Commission.
Contact:CytokineticsDiane WeiserVice President,
Corporate Communications, Investor Relations(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024